Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Free Cash Flow (2022 - 2025)

Taysha Gene Therapies' Free Cash Flow history spans 4 years, with the latest figure at -$23.8 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 9.84% year-over-year to -$23.8 million; the TTM value through Sep 2025 reached -$84.7 million, down 2.22%, while the annual FY2024 figure was -$81.6 million, 6.13% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$23.8 million at Taysha Gene Therapies, down from -$20.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $32.6 million in Q4 2022 and bottomed at -$49.6 million in Q2 2022.
  • The 4-year median for Free Cash Flow is -$21.6 million (2024), against an average of -$20.9 million.
  • The largest YoY upside for Free Cash Flow was 62.28% in 2023 against a maximum downside of 159.94% in 2023.
  • A 4-year view of Free Cash Flow shows it stood at $32.6 million in 2022, then crashed by 159.94% to -$19.6 million in 2023, then increased by 6.43% to -$18.3 million in 2024, then dropped by 29.9% to -$23.8 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Free Cash Flow are -$23.8 million (Q3 2025), -$20.6 million (Q2 2025), and -$22.0 million (Q1 2025).